Patents by Inventor Lawrence N. Tumey

Lawrence N. Tumey has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Heteroaryl sulfone-based conjugation handles, methods for their preparation, and their use in synthesizing antibody drug conjugates
    Patent number: 11712480
    Abstract: The present invention is directed to novel heteroaryl sulfone-based conjugation handles of the formula: (wherein R1, R2, Het, D, E, X, Y, Z, m, n, p, q, r, s and t are as defined herein), methods for their preparation, their use in synthesizing antibody drug conjugates, and the resulting antibody drug conjugates made with components having heteroaryl sulfone-based conjugation handles.
    Type: Grant
    Filed: July 31, 2017
    Date of Patent: August 1, 2023
    Assignee: Pfizer Inc.
    Inventors: Russell George Dushin, Daniel P. Uccello, Jeremy Starr, Ye Che, Mark Flanagan, Jeffrey M. Casavant, Christopher John O'Donnell, Gary Frederick Filzen, Jennifer Young, Joseph A. Abramite, Lawrence N. Tumey, Ludivine Moine, Adam Matthew Gilbert, Lee R. Roberts
  • Bifunctional cytotoxic agents containing the CTI pharmacophore
    Patent number: 11365263
    Abstract: The present invention is directed to novel bifunctional CTI-CTI and CBI-CTI dimers of the formula: F1-L1-T-L2-F2 where F1, L1, T, L2 and F2 are as defined herein, useful for the treatment for proliferative diseases, where the inventive dimers can function as stand-alone drugs, payloads in antibody-drug-conjugates (ADCs), and linker-payload compounds useful in connection with the production or administration of such ADCs; and to compositions including the aforementioned dimers, linker-payloads and ADCs, and methods for using these dimers, linker-payloads and ADCs, to treat pathological conditions including cancer.
    Type: Grant
    Filed: November 6, 2020
    Date of Patent: June 21, 2022
    Assignee: PFIZER INC.
    Inventors: Andreas Maderna, Chakrapani Subramanyam, Lawrence N. Tumey, Zecheng Chen, Jeffrey M. Casavant
  • HETEROARYL SULFONE-BASED CONJUGATION HANDLES, METHODS FOR THEIR PREPARATION, AND THEIR USE IN SYNTHESIZING ANTIBODY DRUG CONJUGATES
    Publication number: 20210308276
    Abstract: The present invention is directed to novel heteroaryl sulfone-based conjugation handles of the formula: (wherein R1, R2, Het, D, E, X, Y, Z, m, n, p, q, r, s and t are as defined herein), methods for their preparation, their use in synthesizing antibody drig conjugates, and the resulting antibody drig conjugates made with components having heteroaryl sulfone-based conjugation handles.
    Type: Application
    Filed: July 31, 2017
    Publication date: October 7, 2021
    Applicant: PFIZER INC.
    Inventors: Russell George DUSHIN, Daniel P. UCCELLO, Jeremy STARR, Ye CHE, Mark FLANAGAN, Jeffrey M. CASAVANT, Christopher John O'DONNELL, Gary Frederick FILZEN, Jennifer YOUNG, Joseph A. ABRAMITE, Lawrence N. TUMEY, Ludivine MOINE, Adam Matthew GILBERT, Lee R. ROBERTS
  • BIFUNCTIONAL CYTOTOXIC AGENTS CONTAINING THE CTI PHARMACOPHORE
    Publication number: 20210061923
    Abstract: The present invention is directed to novel bifunctional CTI-CTI and CBI-CTI dimers of the formula: F1-L1-T-L2-F2 where F1, L1, T, L2 and F2 are as defined herein, useful for the treatment for proliferative diseases, where the inventive dimers can function as stand-alone drugs, payloads in antibody-drug-conjugates (ADCs), and linker-payload compounds useful in connection with the production or administration of such ADCs; and to compositions including the aforementioned dimers, linker-payloads and ADCs, and methods for using these dimers, linker-payloads and ADCs, to treat pathological conditions including cancer.
    Type: Application
    Filed: November 6, 2020
    Publication date: March 4, 2021
    Applicant: PFIZER INC.
    Inventors: Andreas MADERNA, Chakrapani SUBRAMANYAM, Lawrence N. TUMEY, Zecheng CHEN, Jeffrey M. CASAVANT
  • Bifunctional cytotoxic agents containing the CTI pharmacophore
    Patent number: 10870706
    Abstract: The present invention is directed to novel bifunctional CTI-CTI and CBI-CTI dimers of the formula: F1-L1-T-L2-F2 where F1, L1, T, L2 and F2 are as defined herein, useful for the treatment for proliferative diseases, where the inventive dimers can function as stand-alone drugs, payloads in antibody-drug-conjugates (ADCs), and linker-payload compounds useful in connection with the production or administration of such ADCs; and to compositions including the aforementioned dimers, linker-payloads and ADCs, and methods for using these dimers, linker-payloads and ADCs, to treat pathological conditions including cancer.
    Type: Grant
    Filed: March 15, 2016
    Date of Patent: December 22, 2020
    Assignee: PFIZER INC.
    Inventors: Andreas Maderna, Chakrapani Subramanyam, Lawrence N. Tumey, Zecheng Chen, Jeffrey M. Casavant
  • Tubulysin analogs and methods for their preparation
    Patent number: 10723727
    Abstract: The present invention is directed to novel cytotoxic tubulysin analogs and derivatives, to antibody drug conjugates thereof, and to methods for using the same to treat medical conditions including cancer.
    Type: Grant
    Filed: January 27, 2017
    Date of Patent: July 28, 2020
    Assignee: Pfizer Inc.
    Inventors: Chakrapani Subramanyam, Lawrence N. Tumey, Longfei Xie, Carolyn Leverett, Beth C. Vetelino, Sai Chetan K. Sukuru, Sarah Hudson, Venkata Ramana Doppalapudi, Abhijit S. Bhat
  • CALICHEAMICIN DERATIVES AND ANTIBODY DRUG CONJUGATES THEREOF
    Publication number: 20190345186
    Abstract: The present invention is directed to novel calicheamicin derivatives useful as payloads in antibody-drug-conjugates (ADC's), and to payload-linker compounds and ADC compounds comprising the same; to pharmaceutical compositions comprising the same and to methods for using the same to treat pathological conditions such as cancer.
    Type: Application
    Filed: January 10, 2018
    Publication date: November 14, 2019
    Applicant: PFIZER INC.
    Inventors: Omar Khaled Ahmad, Stephen Paul Brown, Kenneth John Dirico, Russell Dushin, Gary Frederick Filzen, Sujiet Puthenveetil, Pavel Strop, Chakrapani Subramanyam, Lawrence N. Tumey
  • TUBULYSIN ANALOGS AND METHODS FOR THEIR PREPARATION
    Publication number: 20180362519
    Abstract: The present invention is directed to novel cytotoxic tubulysin analogs and derivatives, to antibody drug conjugates thereof, and to methods for using the same to treat medical conditions including cancer.
    Type: Application
    Filed: January 27, 2017
    Publication date: December 20, 2018
    Applicants: PFIZER INC., CovX Technologies Ireland Limited
    Inventors: Chakrapani SUBRAMANYAM, Lawrence N. TUMEY, Longfei XIE, Carolyn LEVERETT, Beth C. VETELINO, Sai Chetan K. SUKURU, Sarah HUDSON, Venkata Ramana DOPPALAPUDI, Abhijit S. BHAT
  • BIFUNCTIONAL CYTOTOXIC AGENTS CONTAINING THE CTI PHARMACOPHORE
    Publication number: 20160271270
    Abstract: The present invention is directed to novel bifunctional CTI-CTI and CBI-CTI dimers of the formula: F1-L1-T-L2-F2 where F1, L1, T, L2 and F2 are as defined herein, useful for the treatment for proliferative diseases, where the inventive dimers can function as stand-alone drugs, payloads in antibody-drug-conjugates (ADCs), and linker-payload compounds useful in connection with the production or administration of such ADCs; and to compositions including the aforementioned dimers, linker-payloads and ADCs, and methods for using these dimers, linker-payloads and ADCs, to treat pathological conditions including cancer.
    Type: Application
    Filed: March 15, 2016
    Publication date: September 22, 2016
    Applicant: Pfizer Inc.
    Inventors: Andreas MADERNA, Chakrapani SUBRAMANYAM, Lawrence N. TUMEY, Zecheng CHEN, Jeffrey M. CASAVANT
  • Cyclic n-hydroxy imides as inhibitors of flap endonuclease and uses thereof
    Patent number: 7947691
    Abstract: Acrylic n-hydroxy imides and their use in pharmaceutical compositions and in the inhibition of flap endonuclease are disclosed.
    Type: Grant
    Filed: July 20, 2005
    Date of Patent: May 24, 2011
    Assignee: Athersys, Inc.
    Inventors: Lawrence N. Tumey, Youssef Bennani, Bayard Huck, David C. Bom
  • Substituted Azepine Derivatives As Serotonin Receptor Modulators
    Publication number: 20100190772
    Abstract: The present invention generally relates to compounds and pharmaceutical compositions containing the compounds. More specifically, compounds of the present invention are hexahydroazepinoindole and octahydroazepinoindole compounds. These compounds are serotonin receptor (5-HT) ligands and are useful for treating diseases, disorders, and conditions wherein modulation of the activity of serotonin receptors (5-HT) is desired (e.g. anxiety, depression and obesity).
    Type: Application
    Filed: April 1, 2010
    Publication date: July 29, 2010
    Inventors: Youssef L. Bennani, Michael J. Robarge, David C. Bom, Norbert Varga, Lawrence N. Tumey
  • Substituted azepine derivatives as serotonin receptor modulators
    Patent number: 7718647
    Abstract: The present invention generally relates to a series of compounds, to pharmaceutical compositions containing the compounds, and to use of the compounds and compositions as therapeutic agents. More specifically, compounds of the present invention are hexahydroazepinoindole and octahydroazepinoindole compounds. These compounds are serotonin receptor (5-HT) ligands and are useful for treating diseases, disorders, and conditions wherein modulation of the activity of serotonin receptors (5-HT) is desired (e.g. anxiety, depression and obesity).
    Type: Grant
    Filed: June 29, 2005
    Date of Patent: May 18, 2010
    Assignee: Athersys, Inc.
    Inventors: Youssef L. Bennani, Michael J. Robarge, David C. Bom, Norbert Varga, Lawrence N. Tumey
  • Cyclic N-Hydroxy Imides as Inhibitors of Flap Endonuclease and Uses Thereof
    Publication number: 20080287465
    Abstract: Acrylic n-hydroxy imides and their use in pharmaceutical compositions and in the inhibition of flap endonuclease are disclosed.
    Type: Application
    Filed: July 20, 2005
    Publication date: November 20, 2008
    Applicant: ATHERSYS, INC.
    Inventors: Lawrence N. Tumey, Youssef Bennani, Bayard Huck, David C. Bom